Showing papers on "Antitussive Agent published in 1990"
TL;DR: The data suggest that U-50, 488H and U-62, 066E exert their antitussive effect on rats through stimulation of κ-opioid receptors, and the system that involves 5-HT1 receptors may be more important than theSystem that involves5-HT2 receptors.
45 citations
4 citations
Journal Article•
3 citations
TL;DR: L-tryptophan can be considered to be a useful constituent of antitussive preparations and the liability with respect to physical dependence on dihydrocodeine was not enhanced by the simultaneous administration of L-t Kryptophan.
Abstract: The effects of L-tryptophan and the major constituents of cough medicines on the antitussive effect of dihydrocodeine were examined in a comparative study with anesthetized rats. The antitussive effect of dihydrocodeine was enhanced by simultaneous administration of noscapine or methylephedrine. In rats treated with noscapine and methylephedrine together, the effect of dihydrocodeine was more markedly enhanced. Furthermore, L-tryptophan reduced by half the antitussive ED50 (AtD50) of dihydrocodeine. There was no difference between the AtD50 of dihydrocodeine when administered in combination with noscapine and methylephedrine and that of dihydrocodeine when combined with noscapine and L-tryptophan. The AtD50 of noscapine and dextromethorphan was also reduced by about half when what was administered with L-tryptophan. By contrast, the liability with respect to physical dependence on dihydrocodeine was not enhanced by the simultaneous administration of L-tryptophan. These results suggest that L-tryptophan can be considered to be a useful constituent of antitussive preparations.
3 citations
Journal Article•
2 citations
Patent•
26 Feb 1990
TL;DR: In this article, a tryptophan-contg. medicinal composition for antitussive therapy is presented, which is obtained by incorporating the active ingredient with pref. dextromethorphan and common medicinal support at one's discretion followed by pharmaceutical manufacturing by conventional means.
Abstract: PURPOSE: To orally administer a tryptophan-contg. medicinal composition for antitussive therapy. CONSTITUTION: This composition, which contains tryptophan as active ingredient, is obtained by incorporating the active ingredient with pref. an antitussive agent for oral use (e.g. dextromethorphan (salt)) and also common medicinal support at one's discretion followed by pharmaceutical manufacturing by conventional means. In this case, the weight ratio of the tryptophan to antitussive agent is (2:1) to (5,000:1), and these two ingredients account for 5-95wt.% and 1-50wt.% of this composition for solid and liquid formulations, respectively. The solid formulations include tablets, capsules, granules, lozenges and bulk powders, while, the liquid formulations include solutions, suspensions, syrups and emulsions. The daily dose of this composition is 2.0-3,000mg/kg.
2 citations